mrx-2843

InvivoChem Cat #:V5202CAS #:1429882-07-4Purity >=98%

Description: MRX-2843 (also known as UNC2371) is a novel, potent and orally bioactive small-molecule inhibitor of MERTK and FLT3. MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. MRX-2843 in combination with an irreversible EGFR TKI as a novel strategy for treatment of patients with wtEGFR NSCLC. MRX-2843 treatment induces apoptosis and inhibits colony formation in AML cell lines and primary patient samples expressing MERTK and/or FLT3-ITD, with a wide therapeutic window compared with that of normal human cord blood cells.

References: JCI Insight. 2016 Mar; 1(3):e85630.

-20C for 3 years in powder form

Synonym: MRX-2843; MRX 2843; MRX2843; UNC2371; UNC-2371; UNC 2371; UNC2371A; UNC-2371A; UNC 2371A;
Chemical Name: (1r, 4r)-4-(2-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2, 3-d]pyrimidin-7-yl)cyclohexanol
InChi Key: LBEJYFVJIPQSNX-SOAUALDESA-N
InChi Code: InChI=1S/C29H40N6O/c1-33-14-16-34(17-15-33)19-22-4-6-23(7-5-22)27-20-35(24-8-10-25(36)11-9-24)28-26(27)18-31-29(32-28)30-13-12-21-2-3-21/h4-7, 18, 20-21, 24-25, 36H, 2-3, 8-17, 19H2, 1H3, (H, 30, 31, 32)/t24-, 25-
SMILES Code: O[CH]1CC[CH](N2C=C(C3=CC=C(CN4CCN(C)CC4)C=C3)C5=CN=C(NCCC6CC6)N=C52)CC1